media – Page 37 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Cardinal Health Acquires ION for $1.115 Billion

Recently, Cardinal Health, the world’s ninth largest medical device company, announced that it has signed a final agreement to acquire Integrated Oncology Network (ION) for $1.115 billion (approximately RMB 7.861 billion) in cash to expand its oncology services business. INO is an independent community cancer center operator with over 50 clinics, more than 100 suppliers, and over 1000 healthcare workers in 10 states across the United States. It provides comprehensive care services for communities in areas such as medical oncology, radiation oncology, urology, and diagnostic testing. After this acquisition, all assets of ION will be integrated into the Navista Cancer Care division of Gardenor, and ION’s clinics will also receive Navista’s artificial intelligence analysis capabilities, as well as PPS Analytics platform support previously acquired by Gardenor through the acquisition of Specialty Networks. Navista is a subsidiary of Gardenor, a cancer diagnosis and treatment department jointly established with oncologists and clinic ...
- Source: drugdu
- 105
- September 25, 2024
【EXPERT Q&A】What is the process of exporting drugs to Mexico?

Drugdu.com expert’s response: The process of exporting pharmaceuticals to Mexico involves multiple stages, which can be outlined in detail as follows: I. Pre-Export Preparation （1）Understanding Regulations and Policies: Conduct thorough research on Mexican laws and regulations pertaining to pharmaceutical imports, including import permit requirements, quality standards, prohibited and restricted medicinal ingredients. Verify the legality of the drugs in Mexico and assess market demand. （2）Selecting Partners: Identify logistics companies with expertise in pharmaceutical exports to Mexico, ensuring they possess the necessary qualifications and capabilities. Communicate with the logistics partner to clarify responsibilities and benefits, finalizing a cooperation agreement. （3）Preparing Necessary Documentation: Assemble essential export documents such as export permits, inspection reports, and certificates of origin. Prepare Mexican-required import documents, including import permits, health certificates, and others. II. Pharmaceutical Preparation and Packaging （1）Pharmaceutical Preparation: Ensure drug quality adheres to Mexican import standards. Prepare related materials like drug formulas, instructions, and production batch ...
- Source: drugdu
- 95
- September 25, 2024
Personnel changes in core positions at Medtronic

Recently, Medtronic, the global leader in medical devices, announced that Jorie Soskin has been appointed as the new Vice President and General Manager of TAVR and Congenital Heart Disease businesses. According to data, Jorie Soskin is a seasoned veteran of Medtronic. Since the beginning of this year, multiple personnel changes have been reported at Medtronic. As a giant in the healthcare industry, every decision made by Medtronic may have a profound impact on the entire industry. The personnel changes in core positions also mean a new leadership style and strategic direction. 15 year veteran, helping the high-quality development of TAVR field As mentioned earlier, Jorie Soskin, the newly appointed Vice President and General Manager of TAVR and Congenital Heart Disease Business, is a seasoned veteran of Medtronic, currently residing in Minneapolis, Minnesota, USA. She holds a Bachelor of Arts degree in International Asian Studies from Boston College and has also ...
- Source: drugdu
- 86
- September 25, 2024
Junshi Biosciences’ PD-1 Approved in the EU, Achieving Market Launch in China, the US, and Europe

As a result, Toripalimab has become the first and only PD-1 approved for the treatment of nasopharyngeal carcinoma in Europe, as well as the only first-line treatment drug for advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression. Prior to this, Toripalimab had already been approved in China and the US. On July 28, Junshi Biosciences announced that Toripalimab’s marketing authorization application received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the aforementioned indications. Toripalimab injection (Chinese trade name: Tuoyi®) is the first domestically approved PD-1 monoclonal antibody in China. In December 2018, the National Medical Products Administration conditionally approved Toripalimab for the treatment of unresectable or metastatic melanoma in patients who had failed prior systemic therapy. As of now, Toripalimab has received approval for seven indications in China, covering the treatment of melanoma, nasopharyngeal carcinoma, ...
- Source: drugdu
- 102
- September 25, 2024
Wealth myth” of GLP-1

Recently, the Lasker Award, an important award in the field of biomedicine known as the “vane” of the Nobel Prize, was announced. Among them, the “Clinical Medical Research Award” was awarded to Joel Habener (Massachusetts General Hospital), Lotte Bjerre Knudsen (Novo Nordisk) ) and Svetlana Mojsov (Rockefeller University). The reason for the award is that they discovered and developed GLP-1-based drugs, which revolutionized the treatment of obesity. GLP-1, glucagon-like peptide-1, is a peptide hormone encoded by the human glucagon gene and secreted by intestinal L cells. It can promote the synthesis and secretion of insulin and suppress appetite. Delaying the emptying of gastric contents, etc. Representative products include Novo Nordisk’s semaglutide and Eli Lilly’s tilpotide. It is worth mentioning that the research on GLP-1 has not only received attention from academic awards, but also brought “vast wealth” to companies in the industrial chain due to the huge market demand. The ...
- Source: drugdu
- 94
- September 25, 2024
The audit storm continues! Strictly investigate hospital account loopholes

Recently, the National Audit Office released the audit dynamics “Convening a video conference on audit rectification work, conducting public health construction project audits…” It mentioned that the Audit Bureau of Wuhan City, Hubei Province, conducted an audit of public health construction projects at the municipal level. The Audit Bureau of Wuhan City examines whether the construction projects comply with relevant plans, industrial and industry policies, whether the funds are raised in place, whether the project approval procedures are complete, and whether the projects are advanced on schedule, to promote the implementation of public health projects. Pay attention to the construction of major epidemic treatment bases at the municipal level, review the construction of negative pressure wards and negative pressure operating rooms, whether infectious disease beds, normal beds, and peacetime and wartime beds meet the planning requirements, the reserve of hemodialysis machines in designated hospitals meets the standards, whether the reserves ...
- Source: drugdu
- 68
- September 25, 2024
When will it become the global TOP20? Mindray’s latest response

Recently, Mindray Medical disclosed the record of the investor relations event held on September 14, and answered several questions of concern to investors. Among them, “North American growth is lower than expected”, “future performance guidance targets”, mergers and acquisitions, AI medical layout and other issues have become the focus of this meeting. In this regard, Mindray Medical also answered from relevant perspectives. Among them, when mentioning future performance guidance, Mindray Medical said that based on the current situation, the company still has strong confidence that it can successfully achieve the goal of global medical device TOP20 in 2025 at the latest according to the established plan. Achieve global medical device TOP20 at the end of 2025 at the latest. According to the data, Mindray Medical mainly has three major production lines: life information and support, in vitro diagnosis and medical imaging. In recent years, it has also begun to focus ...
- Source: drugdu
- 70
- September 25, 2024
CHMP recommends H drug for EU market launch

Henlius Biopharmaceutical Editor September 23, 2024 09:21 Shanghai H drug Hans form ® It is the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC H drug Hans form ® Expected to become the first and only anti-PD-1 monoclonal antibody marketed in Europe for first-line treatment of ES-SCLC H drug Hans form ® Currently approved for market in countries such as China, Indonesia, Cambodia, and Thailand, benefiting approximately 80000 patients On September 20, 2024, Fosun Pharma (2696. HK) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the company’s independently developed anti-PD-1 monoclonal antibody H drug, Hansid ® (Sullimumab) has received positive approval for marketing authorization, and it is recommended to approve its indication for first-line treatment of extensive stage small cell lung cancer (ES-SCLC). In 2023, Fosun Pharma partnered with Intas to grant exclusive development and commercialization rights for ...
- Source: drugdu
- 77
- September 24, 2024
EMBO J | Jie Yunli team reveals heterogeneity mechanism of glial cells

BioArt In the brains of mammals, in addition to a large number of neurons, there are also a large number of glial cells. These glial cells are widely involved in various aspects of advanced brain functions. Among them, astrocytes, as one of the most abundant glial cells in the mammalian brain, play a crucial role in the functioning of the brain, including participating in synaptic pruning, formation of the blood-brain barrier, and regulation of brain homeostasis balance. Moreover, an increasing number of studies indicate that astrocytes are directly involved in the processing of neural circuit information, and their developmental disorders may trigger various brain diseases. It is worth noting that the morphology and transcriptome characteristics of astrocytes exhibit high heterogeneity in different brain regions and even within the same brain region. During the development of the brain, the origin of astrocytes, namely the location of neural stem cells, determines the ...
- Source: drugdu
- 98
- September 24, 2024
Dental equipment leader, completes important acquisition

Dental equipment pioneer Henry Schein announced that it has completed the acquisition of Shield Healthcare Inc. Shield Healthcare Inc. is a device company that directly provides home care medical products to patients. Henry Schein announced this transaction last year. 01 Enters the field of household appliances In August 2023, Henry Schein announced that he had signed an agreement to acquire a majority stake in Shield Healthcare, Inc. On the basis of Henry Schein’s acquisition of Prism Medical Products LLC in 2021, Shield Healthcare will expand Henry Schein’s existing medical business by providing diversified product series, including incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes products. In addition, it will provide patients with continuous blood glucose monitoring devices directly at home. As the healthcare industry continues to shift towards home care, we have expanded our business of directly providing medical products to patients through our partnership with Shield Healthcare, ...
- Source: drugdu
- 75
- September 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.